Page 108 | Certara

Press Coverage

The Challenging Road to Developing an Integrated Platform for Drug Discovery and Precision Medicine Using the Power of Pharmacometrics

We have often seen Dr. Hwi-yeol (Thomas) Yun, Associate Professor/Adjunct Professor at the College of…

CertaraFebruary 7, 2022

Blog

What is the FDA’s Project Optimus & How Will it Affect Oncology Drug Development?

Project Optimus is an initiative proposed by the U.S. Food and Drug Administration’s Oncology Center…

CertaraFebruary 2, 2022

On-Demand Webinar

Improved Workflow and Expanded functionality of RsNLME v1.1

R Speaks NLME (RsNLME) is a collection of R packages and companion RShiny apps that…

CertaraJanuary 31, 2022

Blog

Choosing an eCTD Submissions Vendor: Your Complete Checklist

September 3, 2025 Selecting the right electronic submission vendor for regulatory submissions to health authorities…

CertaraJanuary 28, 2022

Blog

Don’t Forget About Safety! How to Assess Drug Candidate Safety in Early Clinical Development

This blog will reflect on 3 things drug developers should pay attention to regarding safety…

CertaraJanuary 24, 2022

Video

Certara’s Simcyp® Simulator Demo

The Simcyp PBPK Simulator is the industry leader and most widely adopted platform for PBPK…

CertaraJanuary 20, 2022

Press Coverage

Getting Results Faster – Supporting Physicians and Pharmacists with Biosimulation Technologies

Certara’s Phoenix biosimulation software platform is widely used for non-compartmental analysis (NCA), pharmacokinetic/pharmacodynamic (PK/PD), and…

CertaraJanuary 19, 2022

Video

R Speaks NLME (RsNLME) Overview

This recording shows an overall review of RsNLME using Pirana and an extensive explanation on…

CertaraJanuary 19, 2022

White Paper

The Essential Components of Your Drug’s Biomarker Strategy

CertaraJanuary 14, 2022

On-Demand Webinar

What Oncology Drug Developers Should Expect from the FDA’s Project Optimus

Historically, the dosing strategy for oncology drugs has focused on the maximum tolerated dose. This…

CertaraJanuary 13, 2022

The Challenging Road to Developing an Integrated Platform for Drug Discovery and Precision Medicine Using the Power of Pharmacometrics

What is the FDA’s Project Optimus & How Will it Affect Oncology Drug Development?

Improved Workflow and Expanded functionality of RsNLME v1.1

Choosing an eCTD Submissions Vendor: Your Complete Checklist

Don’t Forget About Safety! How to Assess Drug Candidate Safety in Early Clinical Development

Certara’s Simcyp® Simulator Demo

Getting Results Faster – Supporting Physicians and Pharmacists with Biosimulation Technologies

R Speaks NLME (RsNLME) Overview

The Essential Components of Your Drug’s Biomarker Strategy

What Oncology Drug Developers Should Expect from the FDA’s Project Optimus

Newsletter sign up

Quick links

Solutions

Contact